BRIEF-Balance seen in efficacy, hypoglycemia with Novo's degludec insulin - chair FDA panel

Thu Nov 8, 2012 3:30pm EST

Related Topics

Nov 8 (Reuters) - Novo Nordisk A/S : * Hypoglycemia risk of Novo nordisk's degludec insulin in trials did

not appear significantly higher or lower than oher insulins -- chair of FDA

advisory panel * Balance seemed reasonable between efficacy and hypoglycemia in studies of

degludec - chair of FDA advisory panel * 24-hr half life of degludec makes it unique in terms of long, stable

duration, dosing flexibility - chair of FDA advisory panel

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.